Research Output per year
Background: The bile acid-activated farnesoid X receptor (FXR) is a nuclear receptor regulating bile acid, glucose and cholesterol homeostasis. Obeticholic acid (OCA; also known as INT-747 or 6α-ethyl-chenodeoxycholic acid), a promising drug for the treatment of non-alcoholic steatohepatitis (NASH) and type 2 diabetes, activates FXR. Mouse studies demonstrated that FXR activation by OCA (INT-747) alters hepatic expression of many genes. However, no data are available on the effects of OCA in human liver. Here, we generated gene expression profiles in human precision-cut liver slices (hPCLS) after treatment with OCA.
|Date made available||27 Jan 2016|
Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acidIJssennagger, N., Janssen, A. W. F., Milona, A., Ramos Pittol, J. M., Hollman, D. A. A., Mokry, M., Betzel, B., Berends, F. J., Janssen, I. M., van Mil, S. W. C. & Kersten, S., 2016, In : Journal of Hepatology. p. 1158-1166 64.
Research output: Contribution to journal › Article › Academic › peer-review
Gene expression profiling in human precision-cut liver slices upon treatment with the FXR agonist obeticholic acid
Gene expression profiling in human precision-cut liver slices upon treatment with the FXR agonist obeticholic acid [human]
IJssennagger, N. (Creator), Janssen, A. (Creator), Kersten, S. (Creator), van Mil, S. W. C. (Creator) (27 Jan 2016). Gene expression profiling in human precision-cut liver slices upon treatment with the FXR agonist obeticholic acid [mouse]. Wageningen University.